💡 Quick Answer
On August 27, 2026, the US Court of Appeals for the Fifth Circuit sided with the FDA, Eli Lilly and Novo Nordisk in two rulings that end the compounding industry's legal challenge to the GLP-1 shortage delisting. The practical effect: compounders can no longer use "drug shortage" as the basis for mass-producing copies of Ozempic, Wegovy, Mounjaro or Zepbound. Patient-specific compounding under a 503A pharmacy survives, but on a much narrower legal footing — and both opinions were issued unpublished, which limits how far they reach.
The case that has hung over the cheap-GLP-1 market for nearly two years is now decided. In two separate opinions handed down the same day by the same three-judge panel, the Fifth Circuit affirmed the district court on both counts and left the FDA's shortage determinations standing.
For the several million Americans who have been buying compounded semaglutide or tirzepatide at a fraction of brand pricing, this is the ruling that matters. Here is precisely what the court said, what it did not say, and what changes for you.
What the Court Actually Decided
Two appeals, one panel — Circuit Judges Richman, Duncan and Oldham — both decided per curiam on August 27, 2026:
| Case | Drugs | Brand intervenor | Outcome |
|---|---|---|---|
| No. 25-10600 | Mounjaro, Zepbound (tirzepatide) | Eli Lilly and Company | Affirmed |
| No. 25-10758 | Ozempic, Wegovy (semaglutide) | Novo Nordisk, Inc. | Affirmed |
Both were brought by the Outsourcing Facilities Association and North American Custom Laboratories, trading as FarmaKeio Custom Compounding, and both came up from the Northern District of Texas.
The compounders made two arguments under the Administrative Procedure Act. First, that the FDA should have gone through formal notice-and-comment rulemaking before removing the drugs from the shortage list. Second, that the shortage determination itself was arbitrary and capricious. The panel rejected both.
The nuance most coverage will miss
The tirzepatide opinion is the fuller one; the semaglutide opinion affirms "for the same reasons." But read the semaglutide holding closely:
"Any error by the FDA in not proceeding through the APA's notice and comment procedures was harmless, and the FDA's ultimate action was not arbitrary or capricious."
That is not a finding that the FDA definitely followed correct procedure. It is a finding that even if it did not, the outcome would have been the same, so the error does not undo the decision. Reporting that says the court blessed the FDA's process is overstating it.
Second nuance: both opinions carry the footnote "This opinion is not designated for publication." Under Fifth Circuit Rule 47.5, an unpublished opinion is not binding precedent. The compounders lost, decisively — but the ruling is a narrower legal instrument than a published circuit decision would have been.
How the Shortage Window Opened and Closed
The entire cheap-GLP-1 economy of the last four years rests on one statutory quirk. Federal law bars pharmacies and outsourcing facilities from compounding drugs that are "essentially copies" of an approved product — but that prohibition is temporarily suspended while the drug sits on the FDA's shortage list.
| Date | Event |
|---|---|
| Mar 31, 2022 | Wegovy added to the FDA shortage list |
| Aug 23, 2022 | Ozempic added |
| Dec 2022 | Mounjaro added |
| Apr 2024 | Zepbound added |
| Oct 2, 2024 | FDA declares the tirzepatide shortage resolved |
| Dec 19, 2024 | After a voluntary remand, FDA confirms resolution |
| Aug 27, 2026 | Fifth Circuit affirms on both drugs |
What closed the window was manufacturing. The court records that Eli Lilly spent roughly $23 billion building, expanding and acquiring manufacturing capacity in the US and Europe while its drugs sat on the shortage list, and won approval to sell single-dose vials alongside the original pens. The FDA concluded that supply would "meet or exceed projected demand." Once that was true, the legal basis for copying evaporated.
The FDA did give compounders a runway — it said it would not act on violations for 60 or 90 days depending on the type of compounder, "to avoid unnecessary disruption to patient treatment."
What This Changes for You
The honest answer is that for most people buying compounded GLP-1s today, the ground already shifted in 2025. This ruling closes the last legal avenue for reversing that, rather than triggering something new.
What is now firmly closed
- Shortage-based bulk compounding. 503B outsourcing facilities can no longer mass-produce semaglutide or tirzepatide on a shortage rationale. That was the engine behind the cheapest large-scale offerings.
- The "it's the same molecule, so it's the same thing" pitch. Compounded preparations are not Ozempic, Wegovy, Mounjaro or Zepbound, are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they reach patients.
What still operates
- 503A patient-specific compounding, where a state-licensed pharmacy fills an individual prescription and there is a documented clinical reason the commercial product does not work for that patient — a genuine allergy to an inactive ingredient, or a dose the approved strengths cannot deliver.
- Telehealth programs built on that pathway. They are still running and still shipping. Our telehealth GLP-1 guide covers how the prescribing workflow actually works, and compounded semaglutide's legal status and compounded tirzepatide go deeper on each molecule.
⚠️ The distinction that matters
"Personalization" is a legal test, not a marketing word. A pharmacy adding B12 to semaglutide, or filling a dose between two approved strengths, is making a clinical judgement that has to hold up. Wanting a lower price is not a clinical reason. Programs leaning hard on personalization language while functionally selling a standard product at scale are the ones carrying regulatory risk — and that risk lands on the pharmacy and prescriber, not on you.
What It Means for Prices
Novo Nordisk and Eli Lilly did not spend two years litigating this for the principle. Compounded competition was real pressure — Novo cut its financial guidance several times through 2025 and again in 2026 before raising its outlook on stronger GLP-1 demand, and the company currently guides to adjusted sales growth between 0% and −6% for the year.
Removing a large chunk of low-cost competition is worth a great deal to both companies. What it means for buyers is less predictable than it sounds, because the brands have been moving down-market at the same time. Self-pay vial pricing, LillyDirect and NovoCare have all compressed the gap that made compounding compelling.
If you are re-running the maths, these are the current numbers rather than the 2024 ones: the cheapest GLP-1 options ranked, cheapest tirzepatide, Zepbound out-of-pocket cost, Wegovy out-of-pocket cost, and GLP-1 costs without insurance.
If a brand route is now realistic for you, buying Zepbound online covers the self-pay pathways, and Medicare GLP-1 coverage covers the $50 bridge programme. For the compounding-specific picture, tirzepatide compounding pharmacy status tracks which routes remain open.
What Happens Next
- Further appeal. The Outsourcing Facilities Association can seek rehearing en banc or petition the Supreme Court. Neither is likely to succeed quickly, and the unpublished status cuts both ways — it is a weaker precedent, but also a less attractive vehicle for review.
- Enforcement focus. Attention shifts to whether personalization claims are genuine. Expect FDA warning letters to keep targeting operations that look like bulk manufacturing wearing a 503A label.
- Patent litigation. Separate from this case, Lilly and Novo are pursuing compounders and telehealth sellers directly. Lilly's tirzepatide exclusivity runs to 2027; Novo holds five years of exclusivity on semaglutide plus a further three under a narrower provision.
- Supply is the real variable. The shortage list is not permanent. If demand outruns supply again, the same statutory door reopens.
